Is Healthy Life overvalued or undervalued?

As of 7 November 2025, Healthy Life's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as undervalued, with a PE ratio of 26.24, an EV to EBITDA ratio of 17.44, and a ROCE of 13.87%. In comparison to its peers, Healthy Life's valuation metrics are significantly lower; for instance, Hindustan Unilever has a PE ratio of 53.63, while Nestle India stands at 81.21. Despite the recent decline in stock performance, with a year-to-date return of -66.81% compared to the Sensex's 6.50%, Healthy Life's current valuation appears attractive relative to its peers in the FMCG sector. The company's EV to Sales ratio of 0.50 further supports the notion of undervaluation, especially when juxtaposed against competitors like Britannia Industries, which has a much higher valuation. Overall, Healthy Life presents a compelling investment opportunity at its current price of 17.24.